TNGX News and Press, Tango Therapeutics Inc.

2026-04-08 10:12:40 ET Crystal Adam, President of R&D at Tango Therapeutics (NASDAQ:TNGX) , reported the exercise of 27,000 stock options -- with the underlying common shares immediately sold for approximately $572,000 -- according to an SEC Form 4 filing on April 2, 2026. ...

2026-04-07 11:05:55 ET More on healthcare sector: Routine Vaccines Okay For Now: Investment Implications Of The Court Decision Sector Rotation: Healthcare XLV Should Be The Next Stop VT: Still The Best Approach To Passive Investing Roth Capital Partners flags...

2026-04-04 06:12:51 ET Tango Therapeutics, Inc. ( NASDAQ:TNGX – Get Free Report )’s share price hit a new 52-week high during mid-day trading on Thursday . The company traded as high as $22.20 and last traded at $21.8110, with a volume of 1071164 shares traded. The sto...

2026-03-30 14:10:12 ET More on healthcare stocks IHI: Pullback Creates A Buying Opportunity In High-Growth MedTech Routine Vaccines Okay For Now: Investment Implications Of The Court Decision Sector Rotation: Healthcare XLV Should Be The Next Stop Notable hea...

2026-03-30 13:53:20 ET Adam Crystal, President, R&D of Tango Therapeutics (NASDAQ:TNGX) , reported the sale of 20,251 shares of common stock on March 5, 2026, according to a SEC Form 4 filing . Transaction value based on SEC Form 4 reported price ($15.00); post-transac...

VANCOUVER, British Columbia, March 19, 2026 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary — Big money is moving back into biotech. Institutional investors have been writing some of the largest checks in years, with major financing rounds already closing in the first months...

BOSTON, March 06, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that, effective February 2, 2026, the Compensation Committee of Tango Therapeutics' Board of Directors granted a non-qualified stock option to purchase 367,500 shares of its common stock and 60,000...

2026-03-06 16:02:05 ET Investment Overview The stock of Tango Therapeutics, Inc. ( TNGX ) surged in value yesterday, rising from ~$12.4, to $17.4 per share, a gain of ~43%, as the Boston, Massachusetts based biotech reported its Q4 and annual earnings, and shared business up...

A look at the top 10 most actives in the United States Blue Hat Interactive Entertainment Technology (BHAT) rose 27.2% to $0.0372 on volume of 1,503,563,584 shares Trio Petroleum Corp. (TPET) rose 87.3% to $1.59 on volume of 399,247,798 shares Mobix Labs Inc. (MOBX) rose 5.6% to $0.8659 on ...

2026-03-05 19:15:04 ET Jefferies analyst issues BUY recommendation for TNGX on March 5, 2026 09:46PM ET. The previous analyst recommendation was Buy. TNGX was trading at $16.83 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analy...